Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine
| Autor: | Alfred Saah, Jorma Paavonen, Kristina Elfgren, Matti Lehtinen, Carlos Alberto Petta, John Høye, Gretchen M. Tamms, Sven-Eric Olsson, Luisa L. Villa, Scott Vuocolo, Rosires Pereira de Andrade, Mark T. Esser, Lisa Lupinacci, Agneta Andersson-Ellstrom, Ole-Erik Iversen, Geo von Krogh, Eliav Barr, Katherine E.D. Giacoletti, Ronaldo L.R. Costa, Christian Malm, Grete Riis-Johannessen, Margareta Steinwall |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Sexually transmitted disease
Adult Adolescent Cervical intraepithelial neoplasia Antibodies Viral Genital warts 03 medical and health sciences 0302 clinical medicine Double-Blind Method Immunity medicine Humans 030212 general & internal medicine Papillomavirus Vaccines Immunization Schedule Cervical cancer Human papillomavirus 16 General Veterinary General Immunology and Microbiology Dose-Response Relationship Drug Human papillomavirus 18 business.industry Human papillomavirus 11 Gardasil Papillomavirus Infections Public Health Environmental and Occupational Health Condyloma Acuminatum medicine.disease 3. Good health Infectious Diseases 030220 oncology & carcinogenesis Immunology Molecular Medicine Cervarix business Immunologic Memory medicine.drug Follow-Up Studies |
| Zdroj: | Vaccine. 25(26) |
| ISSN: | 0264-410X |
| Popis: | The duration of protection afforded by vaccines represents a critical test of their utility as public health interventions. Some vaccines induce long-term immunity, while others require booster doses. Vaccines that induce long-term protection are usually characterized by the generation of immune memory. Recent trials of a quadrivalent (types 6, 11, 16, 18) human papillomavirus (HPV) vaccine have demonstrated high efficacy through 5 years of follow-up. We evaluated the extent to which the vaccine is able to generate HPV type-specific immune memory.A total of 552, 16-23-year-old women were enrolled in a double-blind, placebo-controlled study. At enrollment, subjects were randomized in a 1:1 ratio to receive three-dose regimens of quadrivalent HPV vaccine or placebo with 3 years' follow-up. A subset of 241 subjects (n=114 in the quadrivalent HPV vaccine group and n=127 in the placebo group) underwent 2 further years of follow-up. All extension subjects received quadrivalent HPV vaccine at month 60 to examine the extent of immune memory in response to the primary vaccination series.Serum anti-HPV levels declined post-vaccination, but reached a plateau at month 24 that remained stable through month 60. Administration of a challenge dose of vaccine induced a classic anamnestic response, with anti-HPV levels 1 week post-challenge reaching levels observed 1 month following the completion of the three-dose primary series. At 1 month post-challenge, anti-HPV responses were higher than those observed 1-month post-dose 3.A three-dose regimen of quadrivalent HPV vaccine induces high efficacy and stable anti-HPV levels for at least 5 years. Vaccination also induces robust immune memory. These findings suggest that the efficacy of this vaccine will be long lasting. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect